

CLAIMS

1. A process for preparing a paroxetine hydrochloride hydrate, comprising reacting (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylene-  
5 dioxo)phenoxy)methyl]piperidine with hydrogen chloride in the presence of water, and allowing crystals to separate out from the resulting reaction mixture in the presence of water.

2. The process for preparing a paroxetine hydrochloride hydrate according to  
10 claim 1, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxy)methyl]piperidine is reacted with hydrogen chloride in the presence of water, and crystals are allowed to separate out from the resulting reaction mixture, without removing the water used in the reaction.

3. The process for preparing a paroxetine hydrochloride hydrate according to  
15 claim 1 or 2, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxy)methyl]piperidine is reacted with hydrogen chloride in the presence of water, and allowing crystals to separate out from the resulting reaction mixture as they are.

20 4. The process for preparing a paroxetine hydrochloride hydrate according to any one of claims 1 to 3, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxy)methyl]piperidine is reacted with hydrogen chloride in an aromatic hydrocarbon-based organic solvent by adding  
25 hydrochloric acid to the solvent.

5. The process for preparing a paroxetine hydrochloride hydrate according to claim 4, wherein the aromatic hydrocarbon-based organic solvent is toluene.

5 6. The process for preparing a paroxetine hydrochloride hydrate according to any one of claims 1 to 3, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxyethyl]piperidine is reacted with hydrogen chloride in a solvent composed only of water.

10 7. The process for preparing a paroxetine hydrochloride hydrate according to claim 1, 2, 3 or 6, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxyethyl]piperidine is reacted with hydrochloric acid.

15 8. A paroxetine hydrochloride hydrate prepared by a process of any one of claims 1 to 7.

9. A pharmaceutical composition for treating and/or preventing a disorder selected from the group consisting of alcoholism, anxiety syndrome, depression, 20 obsessive-compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, polyphagia, inappetence, social phobia, premenstrual tension syndrome, adolescent depression, trichotillomania, dysthymia and substance abuse, comprising a paroxetine hydrochloride hydrate prepared by a process of any one of claims 1 to 7, and a pharmaceutically acceptable carrier.

25